Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGN-PDL1V |
Synonyms | |
Therapy Description |
SGN-PDL1V is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody targeting CD274 (PD-L1) linked to monomethyl auristatin E (MMAE), which potentially induces cytotoxicity, immune activation, and inhibition of tumor growth (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3154). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-PDL1V | SGNPDL1V|SGN PDL1V | PD-L1/PD-1 antibody 122 | SGN-PDL1V is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody targeting CD274 (PD-L1) linked to monomethyl auristatin E (MMAE), which potentially induces cytotoxicity, immune activation, and inhibition of tumor growth (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3154). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | Advanced Solid Tumor | predicted - sensitive | SGN-PDL1V | Phase I | Actionable | In a Phase I trial, SGN-PDL1V treatment demonstrated manageable safety and resulted in an objective response rate of 27.3% and a median duration of response of 7.9 months in patients with CD274-positive advanced solid tumors (n=55), including non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and esophageal cancer (Ann Oncol (2024) 35 (suppl_2): S486;NCT05208762). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05208762 | Phase I | SGN-PDL1V | A Study of SGN-PDL1V in Advanced Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |